The DOI matches its Crossref record; 217 of the 217 references it cites were found in a registry or an index.
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
Open accessAbstract
Inhibiting glycogen synthase kinase-3 (GSK-3) activity via pharmacological intervention has become an important strategy for treating neurodegenerative and psychiatric disorders. The known GSK-3 inhibitors are of diverse chemotypes and mechanisms of action and include compounds isolated from natural sources, cations, synthetic small-molecule ATP-competitive inhibitors, non-ATP-competitive inhibitors, and substrate-competitive inhibitors. Here we describe the variety of GSK-3 inhibitors with a specific emphasis on their biological activities in neurons and neurological disorders. We further highlight our current progress in the development of non-ATP-competitive inhibitors of GSK-3. The available data raise the hope that one or more of these drug design approaches will prove successful at stabilizing or even reversing the aberrant neuropathology and cognitive deficits of certain central nervous system disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–217 of 217
Hongisto, V., Vainio, J. C., Thompson, R., Courtney, M. J., & Coffey, E. T. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.02227-06 · Cited by 38
Shen, L., Prouty, C. P., Conway, B. R., Westover, L., Xu, J., Look, R. A., Chen, X., Beavers, M. P., Roberts, J. R., Murray, W. V., et al. (2004) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2003.09.047 · Cited by 36
Successful Treatment of Dementia with Lithium
Havens, W. W., & Cole, J. O. (1982) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198202000-00013 · Cited by 31
Rosa, A. O., Egea, J., Martínez, A., García, A. G., & López, M. G. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2008.03.008 · Cited by 31
Song, Y., Qu, Y., Cao, X., & Zhang, W. Y. (2011) · Marine Biotechnology · doi:10.1007/s10126-010-9347-2 · Cited by 30
Zhang, N., Zhong, R., Yan, H., & Jiang, Y. (2010) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2010.01069.x · Cited by 28
Licht-Murava, A., Plotkin, B., Eisenstein, M., & Eldar-Finkelman, H. (2011) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.02.036 · Cited by 28
Self-citationNew Insights into the Autoinhibition Mechanism of Glycogen Synthase Kinase-3β
Ilouz, R., Pietrokovski, S., Eisenstein, M., & Eldar-Finkelman, H. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.08.079 · Cited by 24
Self-citationErmondi, G., Caron, G., Pintos, I. G., Gerbaldo, M., Pérez, M., Pérez, D. I., Gándara, Z., Martínez, A., Gómez, G., & Fall, Y. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2010.12.024 · Cited by 23
Neurites regrowth of cortical neurons by GSK3β inhibition independently of Nogo receptor 1
Seira, O., Gavín, R., Gil, V., Llorens, F., Rangel, A., Soriano, E., & del Río, J. A. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06726.x · Cited by 22
Magiatis, P., Polychronopoulos, P., Skaltsounis, A., Lozach, O., Meijer, L., Miller, D. B., & O'Callaghan, J. P. (2009) · Neurotoxicology and Teratology · doi:10.1016/j.ntt.2009.12.005 · Cited by 21
S4‐01‐04: Phase IIa clinical trial on Alzheimer's disease with NP12, a GSK3 inhibitor
del Ser, T. (2010) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.05.455 · Cited by 20
Lithium may slow progression of amyotrophic lateral sclerosis, but further study is needed
Bedlack, R., Maragakis, N. J., & Heiman-Patterson, T. D. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801762105 · Cited by 15
Alternative Routes of Insulin Delivery
Owens, D. R., Bolli, G. B., & Zinman, B. (2003) · Wiley eBooks · doi:10.1002/0470862092.d0701 · Cited by 15
Leclerc, S., Garnier, M., Eisenbrand, G., Meijer, L., Hoessel, R., Marko, D., Bibb, J. A., Snyder, G. L., Greengard, P., Biernat, J., et al. (2001) · DESY Publication Database (PUBDB) (Deutsches Elektronen-Synchrotron) · Cited by 15
Marine Compounds as a New Source for Glycogen Synthase Kinase 3 Inhibitors
Alonso, D. A., & Martı́nez, A. (2006) · doi:10.1002/0470052171.ch16 · Cited by 11
Silva, R., Mesquita, A., Bessa, J., Sousa, J. C., Sotiropoulos, I., Leao, P., Almeida, O. F. X., & de Sousa, N. (2008) · Max Planck Institute for Plasma Physics · Cited by 6
Cited by
Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseases
Beurel, E., Grieco, S. F., & Jope, R. S. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.016 · Cited by 1,768
Xin, H., Katakowski, M., Wang, F., Qian, J.-Y., Liu, X. S., Ali, M. M., Buller, B., Zhang, Z. G., & Chopp, M. (2017) · Stroke · doi:10.1161/strokeaha.116.015204 · Cited by 533
Targeting hepatic glucose metabolism in the treatment of type 2 diabetes
Rines, A. K., Sharabi, K., Tavares, C. D. J., & Puigserver, P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.151 · Cited by 375
GSK-3 and tau: a key duet in Alzheimer’s disease
Sayas, C. L., & Ávila, J. (2021) · Cells · doi:10.3390/cells10040721 · Cited by 314
“Several GSK-3 inhibitors have been shown to reduce tau phosphorylation in cells and in preclinical studies in mice (reviewed in [188]).”
BackgroundWu, Z.-Q., Li, X.-Y., Hu, C. Y., Ford, M., Kleer, C. G., & Weiss, S. J. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205822109 · Cited by 305
Metadata
- Authors
- Eldar-Finkelman, H., & Martinez, A.
- Venue
- Frontiers in Molecular Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2011
- Volume
- 4
- Pages
- 32-32
- ISSN
- 1662-5099 (ISSN-L)
- OpenAlex
- W1975257189
- Cited by
- 354
- References
- 217
- FWCI
- 10.59
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.